| Bid | 15.74 |
| Market Cap | 4.08B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 5.05 |
| PE Ratio (ttm) | 3.14 |
| Forward PE | n/a |
| Analyst | Sell |
| Ask | 15.95 |
| Volume | 1,689,289 |
| Avg. Volume (20D) | 3,404,636 |
| Open | 15.79 |
| Previous Close | 15.66 |
| Day's Range | 15.73 - 16.05 |
| 52-Week Range | 13.87 - 23.10 |
| Beta | undefined |
About OGN
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology pr...
Analyst Forecast
According to 3 analyst ratings, the average rating for OGN stock is "Sell." The 12-month stock price forecast is $20, which is an increase of 26.30% from the latest price.
Next Earnings Release
Analysts project revenue of $1.59B, reflecting a -0.5% YoY shrinking and earnings per share of 1.03, making a 17.05% increase YoY.
2 months ago · seekingalpha.com
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue g...
